Emerging Carbapenem-Resistant Enterobacteriaceae Infection, Its Epidemiology and Novel Treatment Options: A Review

耐碳青霉烯类肠杆菌科 肠杆菌科 碳青霉烯 美罗培南 医学 抗药性 亚胺培南 肺炎克雷伯菌 抗生素耐药性 感染控制 抗菌剂 微生物学 重症监护医学 生物 抗生素 大肠杆菌 基因 生物化学
作者
Mihret Tilahun,Yeshimebet Kassa,Alemu Gedefie,Melaku Ashagrie Belete
出处
期刊:Infection and Drug Resistance [Dove Medical Press]
卷期号:Volume 14: 4363-4374 被引量:170
标识
DOI:10.2147/idr.s337611
摘要

Infections due to multidrug-resistant Enterobacteriaceae have become major international public health problem due to the inadequate treatment options and the historically lagged pace of development of novel antimicrobial drugs. Inappropriate antimicrobial use in humans and animals coupled with increased global connectivity aided to the transmission of drug-resistant Enterobacteriaceae infections. Carbapenems are the medications of choice for extended-spectrum beta-lactamase and AmpC producers, but alternatives are currently needed because carbapenem resistance is increasing globally. This review pointed to discuss emerging drug-resistant Enterobacteriaceae, its epidemiology and novel treatment options for infections, which date back from 2010 to 2019 by searching Google Scholar, PubMed, PMC, Hinari and other different websites. The occurrence of carbapenem-resistant Enterobacteriaceae is reported worldwide with great regional variability. The rise of carbapenem-resistant Enterobacteriaceae poses a threat to all nations. Enzyme synthesis, efflux pumps, and porin mutations are the main methods by which Enterobacteriaceae acquire resistance to carbapenems. The major resistance mechanism among these is enzyme synthesis. Most carbapenem resistance is caused by three enzyme groups: Klebsiella pneumoniae carbapenemase (Ambler class A), metallo-ß-lactamases (Ambler class B), and oxacillinase-48 (Ambler class D). Ceftazidime-avibactam, which was newly licensed for carbapenemase producers, is the most common treatment option for infections. Meropenem-vaborbactam, imipenem-relebactam, plazomicin, cefiderocol, eravacycline, and aztreonam-avibactam are recently reported to be active against carbapenem-resistant Enterobacteriaceae; and are also in ongoing trials for different populations and combinations with other antibacterial agents. Overall, treatment must be tailored to the patient's susceptibility profile, type and degree of infection, and personal characteristics.

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Akim应助刘书章采纳,获得10
刚刚
苯酚装醇发布了新的文献求助10
1秒前
XinyuLu完成签到,获得积分10
1秒前
1秒前
李健应助罗梦采纳,获得10
2秒前
小蘑菇应助刘钊扬采纳,获得10
3秒前
安详的琳完成签到 ,获得积分10
4秒前
4秒前
镓氧锌钇铀应助Rheton采纳,获得20
5秒前
CipherSage应助ssc采纳,获得10
5秒前
大个应助阔达的冷风采纳,获得10
6秒前
辛勤金连发布了新的文献求助10
6秒前
6秒前
8秒前
8秒前
9秒前
1234发布了新的文献求助10
9秒前
隋菿99发布了新的文献求助10
11秒前
ak14ak47发布了新的文献求助10
11秒前
11秒前
大雁完成签到 ,获得积分10
11秒前
12秒前
科研通AI2S应助南草北树采纳,获得10
12秒前
13秒前
友好灵松发布了新的文献求助10
13秒前
只道寻常发布了新的文献求助10
14秒前
矜戏文发布了新的文献求助10
14秒前
刘书章发布了新的文献求助10
14秒前
14秒前
15秒前
15秒前
健壮念寒完成签到,获得积分20
16秒前
李爱国应助云朵采纳,获得10
17秒前
852应助安详的妙之采纳,获得10
17秒前
ANT发布了新的文献求助10
17秒前
科研通AI2S应助rainning661采纳,获得30
18秒前
友好灵松完成签到,获得积分10
18秒前
合适的龙猫完成签到,获得积分10
18秒前
orixero应助求大佬采纳,获得10
19秒前
19秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
List of 1,091 Public Pension Profiles by Region 1561
Treatise on Geochemistry 1500
Binary Alloy Phase Diagrams, 2nd Edition 1400
Specialist Periodical Reports - Organometallic Chemistry Organometallic Chemistry: Volume 46 1000
Holistic Discourse Analysis 600
Beyond the sentence: discourse and sentential form / edited by Jessica R. Wirth 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 纳米技术 计算机科学 内科学 化学工程 复合材料 物理化学 基因 遗传学 催化作用 冶金 量子力学 光电子学
热门帖子
关注 科研通微信公众号,转发送积分 5514877
求助须知:如何正确求助?哪些是违规求助? 4608422
关于积分的说明 14511277
捐赠科研通 4544455
什么是DOI,文献DOI怎么找? 2490092
邀请新用户注册赠送积分活动 1472035
关于科研通互助平台的介绍 1443840